Satoshi Yoshiba

Clinical Pharmacokinetics of Laninamivir, a Novel Long‐Acting Neuraminidase Inhibitor, After Single and Multiple Inhaled Doses of Its Prodrug, CS‐8958, in Healthy Male Volunteers

Hitoshi Ishizuka, Satoshi Yoshiba, Hiromi Okabe et al. · The Journal of Clinical Pharmacology · 2010 · 66 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +11

Intrapulmonary Distribution and Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Inhaled Administration of Its Prodrug, Laninamivir Octanoate, in Healthy Volunteers

Hitoshi Ishizuka, Kaoru Toyama, Satoshi Yoshiba et al. · Antimicrobial Agents and Chemotherapy · 2012 · 34 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Assessment of the Effects of Renal Impairment on the Pharmacokinetic Profile of Laninamivir, a Novel Neuraminidase Inhibitor, After a Single Inhaled Dose of Its Prodrug, CS-8958

Hitoshi Ishizuka, Satoshi Yoshiba, Kazutaka Yoshihara et al. · The Journal of Clinical Pharmacology · 2010 · 18 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel

Takanari Kitazono, Yasuo Ikeda, Masakatsu Nishikawa et al. · Journal of Thrombosis and Thrombolysis · 2018 · 13 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prodrug, Laninamivir Octanoate, a Long-Acting NeuraminidaseInhibitor, Using an Easy-to-Use Inhaler in Healthy Volunteers

Satoshi Yoshiba, Hiromi Okabe, Hitoshi Ishizuka · Journal of Bioequivalence & Bioavailability · 2011 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13